Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21224905 | 1.00 | ACE (0.41) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL13494198 | 1.00 | ACE (0.41) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL1543546 | 0.85 | ACE (0.56) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL750903 | 0.85 | ACE (0.56) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL187408 | 0.85 | ACE (0.56) | ACERENLMNACYP2C19HSD17B10 | |
| Bromide SCHEMBL6544002 | 0.83 | ACE (0.55) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL258790 | 0.83 | ACE (0.50) | ACEREN | |
| SCHEMBL6478173 | 0.83 | ACE (0.50) | ACEREN | |
| SCHEMBL1950731 | 0.83 | ACE (0.50) | ACEREN | |
| Ammonia Solution, Strong SCHEMBL29036064 | 0.83 | ACE (0.55) | ACERENLMNACYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8183740-A | — | — | None | — | — | JP | disclosed |
| JP-8183739-A | — | — | None | — | — | JP | disclosed |
| CN-121319090-A | Polyoxin hybrid antibiotic Polyoxin AxAnd Polyoxin HxPreparation method and application thereof | 武汉大学 | 2026-01-13 | — | — | CN | disclosed |
| US-20250361273-A1 | METHODS AND COMPOSITIONS | FLAGSHIP PIONEERING INNOVATIONS VII, LLC | 2025-11-27 | — | — | US | disclosed |
| EP-3938372-B1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| EP-3253752-B1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-20220160881-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LIMITED (GB) | 2022-05-26 | — | — | US | disclosed |
| EP-3938372-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MedImmune Limited (GB) | 2022-01-19 | — | — | EP | disclosed |
| CN-113227118-A | Acetylcholine receptor inhibitory peptides and uses thereof | 思亲美有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-6685617-B1 | 4-(((-1-CARBOXY-2-(4-((2,6-DICHLOROBENZOYL)AMINE)PHENYL)ETHYL) AMINO)CARBONYL)-3-OXO-3-THIAZOLIDINEBUTANOIC ACID, USED AS ANTAGONISTS FOR CELLULAR ADHESION MOLECULES, AND ADMINISTERED AS ANTIINFLAMMATORY AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-02-03 | — | — | US | disclosed |
| CN-1313855-A | Inhibitors of alpha4Betal mediated cell adhesion alpha Beta | UPJOHN CO (US) | 2001-09-19 | — | — | CN | disclosed |
| EP-1089989-A1 | INHIBITORS OF ALPHA4BETA1 MEDIATED CELL ADHESION | PHARMACIA & UPJOHN COMPANY (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067230-A1 | INHIBITORS OF α4β1 MEDIATED CELL ADHESION | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |
| JP-H08183740-A | CELL-ANCHORING INHIBITOR AND ANTI-INFLAMMATORY CONTAINING THE SAME | NIPPON STEEL CORP | 1996-07-16 | — | — | JP | disclosed |
| JP-H08183739-A | BLOOD VESSEL-CLOTTING INHIBITOR | NIPPON STEEL CORP | 1996-07-16 | — | — | JP | disclosed |
| EP-0299513-B1 | Azetidine derivatives, compositions and their use | FIDIA GEORGETOWN INST (US) | 1994-10-05 | — | — | EP | disclosed |
| US-4990504-A | Modulate excitatory amino acid receptor system | FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1991-02-05 | — | — | US | disclosed |
| US-4946839-A | ALZHEIMER'S DISEASE | FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1990-08-07 | — | — | US | disclosed |
| EP-0299513-A1 | Azetidine derivatives, compositions and their use | FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361273-A1 | METHODS AND COMPOSITIONS | MC4R, GPR119, MC2R | ACE 2243/4885REN 815/4885LMNA 3576/4885 |
| US-20220160881-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | BCR, UGT2B17, BCL6B | ACE 4809/4885REN 4822/4885LMNA 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.